COPS5 amplification and overexpression confers tamoxifen-resistance in ERα-positive breast cancer by degradation of NCoR

Oestrogen receptor α (ERα) antagonists are used in endocrine therapies for ERα-positive (ERα+) breast cancer patients. Unfortunately the clinical benefit is limited due to intrinsic and acquired drug resistance. Here using integrated genomic and functional studies, we report that amplification and/o...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Renquan, Hu, Xiaobo, Zhou, Junmei, Sun, Jiajun, Zhu, Alan Z., Xu, Xiaofeng, Zheng, Hui, Gao, Xiang, Wang, Xian, Jin, Hongchuan, Zhu, Ping, Guo, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4932188/
https://www.ncbi.nlm.nih.gov/pubmed/27375289
http://dx.doi.org/10.1038/ncomms12044

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4932188/
https://www.ncbi.nlm.nih.gov/pubmed/27375289
http://dx.doi.org/10.1038/ncomms12044

Ejemplares similares